Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Medical Research Council (MRC) Versus Arthritis Centre for Musculoskeletal Ageing Research and the Research into Inflammatory Arthritis Centre Versus Arthritis, University of Birmingham, Birmingham, United Kingdom.
Front Immunol. 2022 Apr 29;13:883287. doi: 10.3389/fimmu.2022.883287. eCollection 2022.
There has been intense research focus on the biological mechanisms underlying the transition from health to disease for rheumatoid arthritis (RA) over recent years, and it is now well established that a state of autoimmunity precedes the development of symptoms for a large proportion of patients. This has led to an increased interest in the identification of at-risk groups and the potential for preventive intervention. The ability of several immunomodulatory agents to delay or prevent RA is under investigation and novel cellular therapies are in development. Preventive approaches are also being assessed in other chronic autoimmune diseases. For example, an anti-CD3 antibody has recently been shown to delay progression to type 1 diabetes in non-diabetic relatives of patients identified as being at high risk. The identification and treatment of individuals as being at risk of a disease where there is a degree of uncertainty around the potential for benefit is socially and ethically challenging. Recently reported difficulties in recruitment to RA prevention trials have underlined the importance of understanding the perspectives of at-risk individuals to identify barriers and facilitators that need to be addressed in order for preventive strategies to be acceptable. Understanding of their preferences for benefits and risks of preventive interventions can inform efficient intervention prioritization, prevention trial design and the development of informational resources for those at risk. In this review we summarize current knowledge of preferences for RA prevention and make recommendations for further research needed to ensure efficient development of preventive therapies and clinical implementation.
近年来,人们对类风湿关节炎 (RA) 从健康到疾病的生物学机制进行了深入研究,现在已经明确,在很大一部分患者中,自身免疫状态先于症状的发展。这导致人们对识别高危人群和潜在的预防干预措施产生了更大的兴趣。目前正在研究几种免疫调节剂延迟或预防 RA 的能力,新型细胞疗法正在开发中。在其他慢性自身免疫性疾病中也在评估预防方法。例如,最近的一项研究表明,在被认为处于高风险的患者的非糖尿病亲属中,一种抗 CD3 抗体可延缓 1 型糖尿病的进展。在某种程度上存在获益不确定性的疾病中,识别和治疗处于风险中的个体在社会和伦理方面具有挑战性。最近报告的 RA 预防试验招募困难强调了了解处于风险中的个体观点的重要性,以确定需要解决的障碍和促进因素,以便使预防策略可以被接受。了解他们对预防干预措施的获益和风险的偏好,可以为高效的干预措施优先级确定、预防试验设计以及为处于风险中的个体开发信息资源提供信息。在这篇综述中,我们总结了目前对 RA 预防偏好的了解,并为进一步研究提出了建议,以确保预防治疗的有效开发和临床实施。